TNAs, or therapeutic nucleic acids, are nucleic acids or closely related compounds that are used to cure disease. TNAs come in a variety of shapes and sizes, but they all have the same mode of action: sequence specific recognition of endogenous nucleic acids via Watson–Crick base pairing. The growing number of FDA-approved nucleic acid therapies shows that diseases can be treated in vivo by addressing their genetic blueprints. Because they target proteins rather than the underlying reasons, traditional therapies typically have transitory therapeutic results. Nucleic acid treatments, on the other hand, can achieve long-lasting or even curative effects by inhibiting, replacing, or altering genes. However, delivery strategies that improve stability, enable internalisation, and boost target affinity are required for clinical translation. Synthetic biology, systems biology, computational biology, bioinformatics, and nanotechnology, among other fields, have accelerated progress and established a new paradigm for nucleic acids in therapy.
Title : Why do 90% of the drugs fail in development? An analysis of 82+ submissions; and a case study of immunotherapy
Narendra Chirmule, Indian Institute of Technology (IIT), India
Title : Eliminating implant failure in humans with nano chemistry: 45,000 cases and counting
Thomas J Webster, Brown University, United States
Title : Evaluating cell compatibility and subcutaneous host response of silk fibroin–chitosan plug composites as potential resorbable implants
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Steps and strides: Cross-species insights into movement and injury
Babak Faramarzi, Western University of Health Sciences, United States
Title : Ancient wisdom, modern science: Biotech services transforming ayurveda
Prashant Sakharam Bhokardankar, Datta Meghe Ayurvedic Medical College Hospital and Research Centre, India
Title : Scientist’s computational lawyer
Julia Sidorova, Instituto Carlos III de Salud (CIBER-EHD), Spain